You are on page 1of 1

ID: 197 Main category: Extracranial Main secondary category: Clinical Topics: Liver, Metastasis, Type of presentation: I am willing to do an oral

session I am willing to do a poster session TITLE STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR LIVER METASTASES FROM COLORECTAL CANCER DESCRIPTION Introduction: The treatment of colorectal oligometastases in various localisations is often related to promising survival. We report the results from a single institution experience at a Danish university hospital on SBRT of liver metastases in patients with colorectal cancer.

Material and Methods: We analysed the outcome of 83 patients with liver metastases from colorectal cancer treated in our department in the period 2000-2008 by SBRT with a central dose of 45 Gy in 3 fractions within 5-8 days. Most of the patients had hepatic progression after local treatment in form of hepatic surgery or radiofrequency ablation (RFA) or after systemic chemo- or targeted therapy. SBRT was only offered to patients who were not amendable for surgical resection or RFA.

Results: After a median follow-up of 17 months the 3 and 5 year overall survival rates were 23 and 8.5 %, respectively. The median survival was 22 months. In a subgroup analysis, the group of patients treated from 2004-2008 had a 3 year survival of 44% and a median survival 33 months in comparison to the patients treated from 2000-2003 who had a 3 year survival of 13% and a median survival 15 months (p=0.002). There was a trend for better survival in patients with small tumors, but this was not significant.

Conclusion: In this group of highly pretreated and poor risk patients, SBRT for liver metastases offered promising outcome with a median survival of 22 months. Patients treated after 2004 had a better survival than patients treated in the years before. Although the systemic treatment has changed, we believe that this is also a result of improved patient selection and treatment. SBRT should be part of the treatment of colorectal liver metastases, even in poor risk patients.